---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-265999"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2021-09-07T23:59:59+00:00"
generated_at: "2026-06-29T05:31:05.176914+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO appoints Dr. Jean Bennett and George Migausky to Board; Luke Beshar resigns

## Summary
- Luke M. Beshar resigned from REGENXBIO Board effective September 3, 2021.
- Dr. Jean Bennett (gene therapy pioneer, co-founder of Spark Therapeutics) elected Class II director.
- George Migausky (former CFO of Dyax) elected Class III director and Audit Committee member.
- Each new director received option for 20,000 shares at $34.98, plus annual retainer.
- Dr. Bennett will serve on Nominating and Corp Gov Committee; Mr. Migausky on Audit Committee.

## SEC filing metadata
- accession: 0001193125-21-265999
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2021-09-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/0001193125-21-265999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/d194596d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-265999
- JSON: https://secwatch.observer/filing/0001193125-21-265999.json
- Plain text: https://secwatch.observer/filing/0001193125-21-265999.txt

## Key facts
- Executive change
  Luke M. Beshar resigned as Director at REGENXBIO Inc..
  - Action: resigned
  - Role: Director
  source text: On September 3, 2021, Luke M. Beshar notified REGENXBIO Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/0001193125-21-265999-index.htm
- Executive change
  Jean Bennett was elected as Class II director at REGENXBIO Inc..
  - Action: elected
  - Role: Class II director
  source text: On September 3, 2021, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee, elected Jean Bennett, M.D., Ph.D., as a Class II director of the Company and a member of the Nominating and Corporate Governance Committee, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/0001193125-21-265999-index.htm
- Executive change
  George V. Migausky was elected as Class III director at REGENXBIO Inc..
  - Action: elected
  - Role: Class III director
  source text: On September 3, 2021, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee, elected George V. Migausky as a Class III director of the Company and a member of the Audit Committee, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/0001193125-21-265999-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.